Sana biotechnology announces publication of preclinical diabetes data in cell stem cell demonstrating insulin independence following transplantation of hypoimmune allogeneic primary islet cells without immunosuppression in a diabetic nhp

Transplant of hip-modified pancreatic islet cells provided lasting glucose control in a fully immunocompetent non-human primate (nhp), enabling the achievement of exogenous insulin independence without immunosuppression for six month study duration
SANA Ratings Summary
SANA Quant Ranking